广生堂(300436.SZ)：创新药子公司参与新发突发与重大传染病防控国家科技重大专项

Core Viewpoint - Guangshengtang (300436.SZ) announced that its subsidiary, Fujian Guangsheng Zhonglin Biotechnology Co., Ltd. (referred to as "Guangsheng Zhonglin"), has received a project completion notice from the National Health Commission for a major national science and technology project focused on the prevention and control of new and major infectious diseases, specifically the "Research on New Combined Treatment Plans for Clinical Cure of Chronic Hepatitis B" [1] Group 1 - Guangsheng Zhonglin is a participant in the Hepatitis B cure project, specifically involved in research for topics one and three of the project [1] - The innovative drugs GST-HG131 and GST-HG141, along with combination therapies, will be used as research medications for the project [1]